RBC Capital Reaffirms Their Hold Rating on Vertex Pharmaceuticals (VRTX)
In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a ...
Evercore ISI Sticks to Its Buy Rating for Vertex Pharmaceuticals (VRTX)
In a report released yesterday, Liisa Bayko from Evercore ISI maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), with ...
Demystifying Vertex Pharmaceuticals: Insights From 17 Analyst Reviews
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...